XLA or SCF from Mass. to Burmuda Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : XLA or SCF from Mass. to Burmuda

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: D.Austin who wrote (869)	4/2/2002 8:24:23 AM
From: D.Austin	Read Replies (1) of 1116

Genelabs Technologies, Inc. discovers and develops a new class of pharmaceutical products that regulate gene expression and proprietary hormone treatment for systemic lupus erythematosus. The company owns key patents covering the development of drugs that selectively regulate gene expression by directly binding to DNA, the fundamental material of genes. The company has investments in other companies, which include Genelabs Diagnostics Pte. Ltd. ("GLD") and Genelabs Biotechnology Co., Ltd. ("GBL"). GBL is Genelab's Taiwan-based affiliate which develops, manufactures and distributes pharmaceutical products in Asia. cbs.marketwatch.com siliconinvestor.com iminfer1k-april2

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next